mir-31-5p的高表达与手术切除后头颈部瘢痕疙瘩复发的风险降低相关。

IF 1.6 4区医学 Q2 OTORHINOLARYNGOLOGY

Laryngoscope Investigative Otolaryngology Pub Date : 2024-12-11 DOI:10.1002/lio2.70040

Albert M. Levin PhD, Oghenefejiro Okifo MD, Katherine Buhl MD, Takahiro Ouchi MD, Bianca Parker MD, Jessica Tan MD, Indrani Datta MS, Xiangguo Dai PhD, Yalei Chen PhD, Nallasivam Palanisamy PhD, Jesse Veenstra MD, PhD, Shannon Carskadon MS, Jia Li PhD, David Ozog MD, Christian E. Keller MD, Dhananjay Chitale MD, MBA, Kevin R. Bobbitt PhD, Howard C. Crawford PhD, Nina Steele PhD, Qing-Sheng Mi MD, PhD, Lamont R. Jones MD, MBA

{"title":"mir-31-5p的高表达与手术切除后头颈部瘢痕疙瘩复发的风险降低相关。","authors":"Albert M. Levin PhD, Oghenefejiro Okifo MD, Katherine Buhl MD, Takahiro Ouchi MD, Bianca Parker MD, Jessica Tan MD, Indrani Datta MS, Xiangguo Dai PhD, Yalei Chen PhD, Nallasivam Palanisamy PhD, Jesse Veenstra MD, PhD, Shannon Carskadon MS, Jia Li PhD, David Ozog MD, Christian E. Keller MD, Dhananjay Chitale MD, MBA, Kevin R. Bobbitt PhD, Howard C. Crawford PhD, Nina Steele PhD, Qing-Sheng Mi MD, PhD, Lamont R. Jones MD, MBA","doi":"10.1002/lio2.70040","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>In this study, we aimed to evaluate mir-31-5p as a prognostic biomarker of keloid disease (KD) recurrence using a retrospective, treatment naïve, surgical cohort of head and neck KD cases from Henry Ford Health.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using a tissue microarray, mir-31-5p expression was measured with miRNAscope, and mir-31-5p cell positivity was determined with QuPath. Logistic regression was used to test the association between mir-31-5p positive cells and KD recurrence at 1 year. In an independent dataset, associations between mir-31-5p and messenger RNA (mRNA) expression were assessed. Ingenuity Pathway Analysis identified target genes and pathways impacted by mir-31-5p.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of the 58 KD patients, 42 (72%) received adjuvant triamcinolone injections, and 8 recurred (14%). mir-31-5p was expressed in 48 (83%) specimens. Increasing mir-31-5p expression was associated with decreased risk of recurrence (<i>p</i> = .031), with an odds ratio of 0.86 (95% CI 0.75–0.98) for each 20% increase in mir-31-5p cellular positivity. This effect persisted with triamcinolone treatment (odds ratio 0.82; 95% CI 0.71–0.95; <i>p</i> = .015). mir-31-5p correlated with gene expression enriched in KD pathways, including mRNA splicing and autophagy.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Taken together, our data supports the association between mir-31-5p expression and KD recurrence. Its potential as a prognostic biomarker should be further investigated.</p>\n </section>\n \n <section>\n \n <h3> Level of Evidence</h3>\n \n <p>Level 2.</p>\n </section>\n </div>","PeriodicalId":48529,"journal":{"name":"Laryngoscope Investigative Otolaryngology","volume":"9 6","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632843/pdf/","citationCount":"0","resultStr":"{\"title\":\"Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection\",\"authors\":\"Albert M. Levin PhD, Oghenefejiro Okifo MD, Katherine Buhl MD, Takahiro Ouchi MD, Bianca Parker MD, Jessica Tan MD, Indrani Datta MS, Xiangguo Dai PhD, Yalei Chen PhD, Nallasivam Palanisamy PhD, Jesse Veenstra MD, PhD, Shannon Carskadon MS, Jia Li PhD, David Ozog MD, Christian E. Keller MD, Dhananjay Chitale MD, MBA, Kevin R. Bobbitt PhD, Howard C. Crawford PhD, Nina Steele PhD, Qing-Sheng Mi MD, PhD, Lamont R. Jones MD, MBA\",\"doi\":\"10.1002/lio2.70040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>In this study, we aimed to evaluate mir-31-5p as a prognostic biomarker of keloid disease (KD) recurrence using a retrospective, treatment naïve, surgical cohort of head and neck KD cases from Henry Ford Health.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Using a tissue microarray, mir-31-5p expression was measured with miRNAscope, and mir-31-5p cell positivity was determined with QuPath. Logistic regression was used to test the association between mir-31-5p positive cells and KD recurrence at 1 year. In an independent dataset, associations between mir-31-5p and messenger RNA (mRNA) expression were assessed. Ingenuity Pathway Analysis identified target genes and pathways impacted by mir-31-5p.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Of the 58 KD patients, 42 (72%) received adjuvant triamcinolone injections, and 8 recurred (14%). mir-31-5p was expressed in 48 (83%) specimens. Increasing mir-31-5p expression was associated with decreased risk of recurrence (<i>p</i> = .031), with an odds ratio of 0.86 (95% CI 0.75–0.98) for each 20% increase in mir-31-5p cellular positivity. This effect persisted with triamcinolone treatment (odds ratio 0.82; 95% CI 0.71–0.95; <i>p</i> = .015). mir-31-5p correlated with gene expression enriched in KD pathways, including mRNA splicing and autophagy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Taken together, our data supports the association between mir-31-5p expression and KD recurrence. Its potential as a prognostic biomarker should be further investigated.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Level of Evidence</h3>\\n \\n <p>Level 2.</p>\\n </section>\\n </div>\",\"PeriodicalId\":48529,\"journal\":{\"name\":\"Laryngoscope Investigative Otolaryngology\",\"volume\":\"9 6\",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632843/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Laryngoscope Investigative Otolaryngology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/lio2.70040\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laryngoscope Investigative Otolaryngology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lio2.70040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：在这项研究中，我们旨在评估mir-31-5p作为瘢痕疙瘩病（KD）复发的预后生物标志物，通过对Henry Ford Health的头颈部KD病例进行回顾性治疗naïve手术队列。方法：采用组织芯片，miRNAscope检测mir-31-5p表达，QuPath检测mir-31-5p细胞阳性。采用Logistic回归检验mir-31-5p阳性细胞与1年KD复发之间的关系。在一个独立的数据集中，评估了mir-31-5p与信使RNA （mRNA）表达之间的关联。匠心途径分析确定了受mir-31-5p影响的靶基因和途径。结果：58例KD患者中，42例（72%）接受了曲安奈德辅助注射，8例（14%）复发。48例（83%）标本中表达Mir-31-5p。mir-31-5p表达增加与复发风险降低相关（p = 0.031）， mir-31-5p细胞阳性每增加20%，优势比为0.86 （95% CI 0.75-0.98）。曲安奈德治疗后这种效果持续存在(优势比0.82；95% ci 0.71-0.95；p = .015)。mir-31-5p与KD通路中富集的基因表达相关，包括mRNA剪接和自噬。结论：综上所述，我们的数据支持mir-31-5p表达与KD复发之间的关联。其作为预后生物标志物的潜力有待进一步研究。证据等级：二级。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection

查看原文本刊更多论文

Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection

Objective

In this study, we aimed to evaluate mir-31-5p as a prognostic biomarker of keloid disease (KD) recurrence using a retrospective, treatment naïve, surgical cohort of head and neck KD cases from Henry Ford Health.

Methods

Using a tissue microarray, mir-31-5p expression was measured with miRNAscope, and mir-31-5p cell positivity was determined with QuPath. Logistic regression was used to test the association between mir-31-5p positive cells and KD recurrence at 1 year. In an independent dataset, associations between mir-31-5p and messenger RNA (mRNA) expression were assessed. Ingenuity Pathway Analysis identified target genes and pathways impacted by mir-31-5p.

Results

Of the 58 KD patients, 42 (72%) received adjuvant triamcinolone injections, and 8 recurred (14%). mir-31-5p was expressed in 48 (83%) specimens. Increasing mir-31-5p expression was associated with decreased risk of recurrence (p = .031), with an odds ratio of 0.86 (95% CI 0.75–0.98) for each 20% increase in mir-31-5p cellular positivity. This effect persisted with triamcinolone treatment (odds ratio 0.82; 95% CI 0.71–0.95; p = .015). mir-31-5p correlated with gene expression enriched in KD pathways, including mRNA splicing and autophagy.

Conclusion

Taken together, our data supports the association between mir-31-5p expression and KD recurrence. Its potential as a prognostic biomarker should be further investigated.